April 24, 2019, 1:22 a.m. EDT

Novartis sales up, lifts guidance

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Donato Paolo Mancini

Novartis AG (NOVN.EB) on Wednesday raised its 2019 core operating income growth guidance as sales continued to grow.

Net profit for the first quarter came in at $1.87 billion, down from $1.97 billion the year prior. Its core operating income grew to $3.25 billion from $2.98 billion the year prior.

Net sales grew to $11.11 billion on-year.

The Swiss drugmaker raised its core operating income growth guidance for 2019 to high-single digit, and confirmed its sales guidance for the year at mid-single digit.

"Novartis is off to a strong start in 2019 with the Mayzent launch, successful Alcon spinoff, and strong operational execution leading us to revise 2019 profit guidance upwards," Chief Executive Vasant Narasimhan said.

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.